Interested in sharing the research? You can order print copies of many research publications.

Order Reprints

Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

Racial and Ethnic Differences in Response to Medicines: Towards Individualized Pharmaceutical Treatment

Recognizing that substantial disparities exist in the quality and quantity of medical care received by minority Americans, especially those of African, Asian and Hispanic heritage, this article reviews the genetic factors that underlie varying responses to medicines observed among different ethnic and racial groups. Pharmacogenetic research in the past few decades has uncovered significant differences among racial and ethnic groups in the metabolism, clinical effectiveness, and side-effect profiles of many clinically important drugs. The authors suggest that these differences must be taken into account in the design of cost management policies such as formulary implementation, therapeutic substitution and step-care protocols. They also suggest that these programs should be broad and flexible enough to enable rational choices and individualized treatment for all patients, regardless of race or ethnic origin.

Press Release

NPC Study Outlines When & How Health Decision-Makers Should Consider Individual Patient Differences

Washington, DC (July 29, 2014)—New research led by the National Pharmaceutical Council (NPC) can assist health care stakeholders to understand when...
Press Release

Specialty Medications: Shifting the Focus From “How Much” We Spend to “How Well” We Spend

Washington, DC, June 9, 2014—As health care decision-makers grapple with how to ensure access to specialty medications, the University of Michigan...
Blog Post

NPC to Discuss Role of Pharmaceuticals, Applying Real-World Evidence at ISPOR Annual Meeting

Planning to attend the International Society for Pharmacoeconomics and Outcomes Research’s (ISPOR) 19th Annual International Meeting in Montreal May...
Blog Post

#TBT: Ethnic Disparities in the Burden and Treatment of Asthma

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...
Press Release

NPC Study Outlines When & How Health Decision-Makers Should Consider Individual Patient Differences

Washington, DC (July 29, 2014)—New research led by the National Pharmaceutical Council (NPC) can assist health care stakeholders to understand when...
Press Release

Specialty Medications: Shifting the Focus From “How Much” We Spend to “How Well” We Spend

Washington, DC, June 9, 2014—As health care decision-makers grapple with how to ensure access to specialty medications, the University of Michigan...
Press Release

NPC, UMD Study: Factors That Cause Different Treatment Responses Are Not Well Understood or Studied

Washington, DC, November 4, 2013—Although researchers and health care providers widely recognize that individuals with stage IV prostate cancer react...
Press Release

National Pharmaceutical Council Comments on PCORI Approval of Research Methodology Standards

Washington, DC (November 19, 2012)—The National Pharmaceutical Council (NPC) today commented on the Patient-Centered Outcomes Research Institute’s (...
Commentary and Testimony Page

NPC Comments on CMS' Proposed Changes to Protected Classes

March 7, 2014Marilyn B. TavennerAdministratorCenters for Medicare & Medicaid ServicesU.S. Department of Health and Human Services200 Independence...
Commentary and Testimony Page

Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?

A growing chorus of voices is publicly sharing data on the effectiveness of treatment options, but one viewpoint has long been shut out of key areas...
Commentary and Testimony Page

The Risks of Standardized Health Care

Think about the last time you visited a medical office. Even at a specialist’s office, chances are that each person waiting for his or her name to be...
Commentary and Testimony Page

Framework Helps ACOs Leverage Pharmaceuticals to Realize Quality, Cost Goals

Medications are more than an item on the balance sheet for health care providers. Pharmaceuticals offer a route to manage costs while achieving...
YouTube Videos

Using Distributed Data Networks to Understand Heterogeneity in Real-World Data

Kimberly Westrich, director of health services research at the National Pharmaceutical Council, explains how large observational datasets like...
YouTube Videos

Taking Patient Variations Into Account

Dr. Lisa Egbuonu-Davis, founder of ROI Squared, explains that data is generally designed toward looking at the mean differences instead of the...
YouTube Videos

Understanding Individual Patients' Health Care Needs

Paul Martino, SVP of Clinical Strategy and Innovation at WellPoint, Inc., explains that it's important for payers and other health care stakeholders...
YouTube Videos

Dr. Allison-Ottey on Individualized Patient Care

Dr. Sharon Allison-Ottey, executive director of the COSHAR Foundation, explains that when it comes to ensuring optimal care for patients, all of...
Blog Post

#TBT: Ethnic Disparities in the Burden and Treatment of Asthma

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...
Blog Post

NPC to Discuss Role of Pharmaceuticals, Applying Real-World Evidence at ISPOR Annual Meeting

Planning to attend the International Society for Pharmacoeconomics and Outcomes Research’s (ISPOR) 19th Annual International Meeting in Montreal May...
Blog Post

The Good, the Bad and the Different

The story line in any spaghetti western generally follows a predictable plot. There are a few shoot outs between the good guys and the bad guys, some...
Blog Post

#TBT: Enrollment Deadline & the Role of Rx in Health Exchanges

As part of our “Throwback Thursday” blog series, we’re taking a look at a research topic that’s currently in the news and tagging it with...

Research

The Emerging Relevance of Heterogeneity of Treatment Effect in Clinical Care: A Study Using Stage IV Prostate Cancer as a Model

Although researchers and health care providers widely recognize that individuals with stage IV...
  •  
  • 1 of 36
  • >

Commentary & Testimony